Leptin-Enhanced JAK-STAT Signaling in Acute Myeloid Leukemia-Derived Mesenchymal Stromal Cells and Its Implications for Disease ProgressionMuzaffar Bhatti, Dennis Dong Hwan Kim, Anthea Travas et al.|Blood|2024Cited by 2
Asciminib Enhances Its Treatment Efficacy Synergistically in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation When Combined with a Reduced Dose of Ponatinib, Dasatinib, or Bosutinib, but Not with Nilotinib or ImatinibHo Jae Han, Dennis Dong Hwan Kim, Jong‐Won Kim et al.|Blood|2023Cited by 2
Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free RemissionMaría Agustina Perusini, Dennis Dong Hwan Kim, Kátia Bórgia Barbosa Pagnano et al.|Blood|2023Cited by 0
New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Evidenced from Mutational Kinetic Analysis Based on Pairwise ComparisonGopila Gupta, Dennis Dong Hwan Kim, May Chiu et al.|Blood|2023Cited by 0
In Vitro Evidence of Synergistically Enhanced Efficacy of Axitinib When Combined with Asciminib in T315I Mutated Chronic Myeloid LeukemiaHo Jae Han, Dennis Dong Hwan Kim, Eunju Park et al.|Blood|2023Cited by 0